Prevalence of non-alcoholic fat disease liver in Russian Federation: meta-analysis
- Authors: Maev I.V.1, Andreev D.N.1, Kucheryavyy Y.A.2
-
Affiliations:
- Yevdokimov Moscow State University of Medicine and Dentistry
- Ilinskaya Hospital
- Issue: Vol 25, No 5 (2023): Gastroenterology
- Pages: 313-319
- Section: Articles
- URL: https://journals.rcsi.science/2075-1753/article/view/131663
- DOI: https://doi.org/10.26442/20751753.2023.5.202155
- ID: 131663
Cite item
Full Text
Abstract
Aim. To systematize data on the prevalence of non-alcoholic fatty liver disease (NAFLD) in the adult population of Russia.
Materials and methods. The studies were searched in the MEDLINE/PubMed and RSCI electronic databases from January 2000 to December 2022 (inclusive). The search included relevant publications in peer-reviewed periodicals in English or Russian; publications with data from cross-sectional/epidemiological studies assessing the prevalence of NAFLD in the Russian population; studies on adult patients with NAFLD; publications with detailed descriptive statistics that allow using the data in the meta-analysis.
Results. The final analysis included 5 studies involving 96.680 subjects. The overall prevalence of NAFLD in the five adult studies analyzed was 27.562% (95% confidence interval – CI 19.056–36.979). The analysis used a random effect model, as there was significant heterogeneity between the results in both groups (I2=99.87%; p<0.0001). In the studies enrolling patients before 2015, the overall prevalence of NAFLD was 22.409% (95% CI 11.550–35.615), whereas, in studies that enrolled patients after 2015, it was 35.874% (95% CI 28.094–44.046). When analyzing multicenter studies only, the overall prevalence of NAFLD was 31.975% (95% CI 24.670–39.755).
Conclusion. This meta-analysis demonstrated that NAFLD is a widespread chronic liver disease in the adult population of Russia, affecting approximately one in four country residents. For a more accurate objectification of the epidemiological structure of NAFLD in Russia, further multicenter studies of unified design are required.
Full Text
##article.viewOnOriginalSite##About the authors
Igor V. Maev
Yevdokimov Moscow State University of Medicine and Dentistry
Email: dna-mit8@mail.ru
ORCID iD: 0000-0001-6114-564X
D. Sci. (Med.), Prof., Acad. RAS
Russian Federation, MoscowDmitry N. Andreev
Yevdokimov Moscow State University of Medicine and Dentistry
Author for correspondence.
Email: dna-mit8@mail.ru
ORCID iD: 0000-0002-4007-7112
Cand. Sci. (Med.)
Russian Federation, MoscowYury A. Kucheryavyy
Ilinskaya Hospital
Email: dna-mit8@mail.ru
ORCID iD: 0000-0001-7760-2091
Cand. Sci. (Med.)
Russian Federation, KrasnogorskReferences
- Маев И.В., Андреев Д.Н., Кучерявый Ю.А., и др. Неалкогольная жировая болезнь печени с позиций современной медицины. М., 2020 [Maev IV, Andreev DN, Kucheriavyi YuA, et al. Nealkogol'naia zhirovaia bolezn' pecheni s pozitsii sovremennoi meditsiny. Moscow, 2020 (in Russian)].
- Ивашкин В.Т., Маевская М.В., Жаркова М.С., и др. Клинические рекомендации Российского общества по изучению печени, Российской гастроэнтерологической ассоциации, Российской ассоциации эндокринологов, Российской ассоциации геронтологов и гериатров и Национального общества профилактической кардиологии по диагностике и лечению неалкогольной жировой болезни печени. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2022;32(4):104-40 [Ivashkin VT, Maevskaya MV, Zharkova MS, et al. Clinical Practice Guidelines of the Russian Scientific Liver Society, Russian Gastroenterological Association, Russian Association of Endocrinologists, Russian Association of Gerontologists and Geriatricians and National Society for Preventive Cardiology on Diagnosis and Treatment of Non-Alcoholic Liver Disease. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2022;32(4):104-40 (in Russian)].
- Маев И.В., Андреев Д.Н. Неалкогольная жировая болезнь печени: механизмы развития, клинические формы и медикаментозная коррекция. Consilium Medicum. Гастроэнтерология. 2012;2:36-9 [Maev IV, Andreev DN. Non-alcoholic fatty liver disease: mechanisms of development, clinical forms and drug correction. Consilium Medicum. Gastroenterology. 2012;2:36-9 (in Russian)].
- Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J Hepatol. 2020;73(1):202-9. doi: 10.1016/j.jhep.2020.03.039
- Маев И.В., Андреев Д.Н., Кучерявый Ю.А., Умярова Р.М. Метаболически ассоциированная жировая болезнь печени. М.: Прима Принт, 2021 [Maev IV, Andreev DN, Kucheriavyi YuA, Umyarova RM. Metabolicheski assotsiirovannaia zhirovaia bolezn' pecheni. Moscow: Prima Print, 2021 (in Russian)].
- Zhang HJ, Wang YY, Chen C, et al. Cardiovascular and renal burdens of metabolic associated fatty liver disease from serial US national surveys, 1999–2016. Chin Med J (Engl). 2021;134(13):1593-601. doi: 10.1097/CM9.0000000000001513
- Nguyen VH, Le MH, Cheung RC, Nguyen MH. Differential Clinical Characteristics and Mortality Outcomes in Persons With NAFLD and/or MAFLD. Clin Gastroenterol Hepatol. 2021;19(10):2172-81.e6. doi: 10.1016/j.cgh.2021.05.029
- Андреев Д.Н., Кучерявый Ю.А. Ожирение как фактор риска заболеваний пищеварительной системы. Терапевтический архив. 2021;93(8):954-62 [Andreev DN, Kucheryavyy YuA. Obesity as a risk factor for diseases of the digestive system. Terapevticheskii Arkhiv (Ter. Arkh). 2021;93(8):954-62 (in Russian)]. doi: 10.26442/00403660.2021.08.200983
- Маев И.В., Кузнецова Е.И., Андреев Д.Н., Дичева Д.Т. Современные и перспективные подходы к диагностике неалкогольной жировой болезни печени. Consilium Medicum. 2015;17(8):20-7 [Maev IV, Kuznetsova EI, Andreev DN, Dicheva DT. Current and future approaches to the diagnosis of non-alcoholic fatty liver disease. Consilium Medicum. 2015;17(8):20-7 (in Russian)].
- Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73-84.
- Le MH, Yeo YH, Li X, et al. 2019 Global NAFLD Prevalence: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2022;20(12):2809-17.e28.
- Younossi ZM, Golabi P, Paik JM, et al. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology. 2023;77(4):1335-47. doi: 10.1097/HEP.0000000000000004
- Драпкина О.М., Ивашкин В.Т. Эпидемиологические особенности неалкогольной жировой болезни печени в России (результаты открытого многоцентрового проспективного исследования-наблюдения DIREGL 01903). Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2014;24(4):32-8 [Drapkina OM, Ivashkin VT. Epidemiologicheskiie osobennosti nealkogol'noi zhirovoi bolezni pecheni v Rossii (rezul'taty otkrytogo mnogotsentrovogo prospektivnogo issledovaniia-nabliudeniia DIREGL 01903). Rossiiskii zhurnal gastroenterologii, gepatologii, koloproktologii. 2014;24(4):32-8 (in Russian)].
- Ивашкин В.Т., Драпкина О.М., Маев И.В., и др. Распространенность неалкогольной жировой болезни печени у пациентов амбулаторно-поликлинической практики в Российской Федерации: результаты исследования DIREG 2. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2015;25(6):31-41 [Ivashkin VT, Drapkina OM, Maev IV, et al. Rasprostranennost' nealkogol'noi zhirovoi bolezni pecheni u patsiientov ambulatorno-poliklinicheskoi praktiki v Rossiiskoi Federatsii: rezul'taty issledovaniia DIREG 2. Rossiiskii zhurnal gastroenterologii, gepatologii, koloproktologii. 2015;25(6):31-41 (in Russian)].
- Комова А.Г., Маевская М.В., Ивашкин В.Т. Принципы эффективной диагностики диффузных заболеваний печени на амбулаторном этапе. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2014;24(5):36-41 [Komova AG, Maievskaia MV, Ivashkin VT. Printsipy effektivnoi diagnostiki diffuznykh zabolevanii pecheni na ambulatornom etape. Rossiiskii zhurnal gastroenterologii, gepatologii, koloproktologii. 2014;24(5):36-41 (in Russian)].
- Евстифеева С.Е., Шальнова С.А., Куценко В.А., и др. Распространенность неалкогольной жировой болезни печени среди населения трудоспособного возраста: ассоциации с социально-демографическими показателями и поведенческими факторами риска (данные ЭССЕ-РФ-2). Кардиоваскулярная терапия и профилактика. 2022;21(9):3356 [Evstifeeva SE, Shalnova SA, Kutsenko VA, et al. Prevalence of non-alcoholic fatty liver disease among the working-age population: associations with socio-demographic indicators and behavioral risk factors (ESSE RF-2 data). Cardiovascular Therapy and Prevention. 2022;21(9):3356 (in Russian)]. doi: 10.15829/1728-8800-2022-3356
- Bikbov MM, Gilmanshin TR, Zainullin RM, et al. Prevalence of non-alcoholic fatty liver disease in the Russian Ural Eye and Medical Study and the Ural Very Old Study. Sci Rep. 2022;12(1):7842. doi: 10.1038/s41598-022-12004-y
- Маев И.В., Андреев Д.Н., Кучерявый Ю.А. Метаболически ассоциированная жировая болезнь печени – заболевание XXI века. Consilium Medicum. 2022;24(5):325-32 [Maev IV, Andreev DN, Kucheryavyy YuA. Metabolically associated fatty liver disease – a disease of the 21st century. Consilium Medicum. 2022;24(5):325-32 (in Russian)]. doi: 10.26442/20751753.2022.5.201532
- Lim S, Kim JW, Targher G. Links between metabolic syndrome and metabolic dysfunction-associated fatty liver disease. Trends Endocrinol Metab. 2021;32(7):500-14. doi: 10.1016/j.tem.2021.04.008
- Buzzetti E, Pinzani M, Tsochatzis EA. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism. 2016;65(8):1038-48. doi: 10.1016/j.metabol.2015.12.012
- Parthasarathy G, Revelo X, Malhi H. Pathogenesis of Nonalcoholic Steatohepatitis: An Overview. Hepatol Commun. 2020;4(4):478-92. doi: 10.1002/hep4.1479
- Martín-Mateos R, Albillos A. The Role of the Gut-Liver Axis in Metabolic Dysfunction-Associated Fatty Liver Disease. Front Immunol. 2021;12:660179. doi: 10.3389/fimmu.2021.660179
- Дичева Д.Т., Андреев Д.Н. Патогенетическое и клиническое значение оси «микробиота – кишечник – печень». Медицинский Совет. 2022;7:69-75 [Dicheva DT, Andreev DN. Pathogenetic and clinical significance of the gut-liver microbiota axis. Medical Council. 2022;7:69-75 (in Russian)].
- Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67(1):328-57. doi: 10.1002/hep.29367
- Xiang Z, Chen YP, Ma KF, et al. The role of ursodeoxycholic acid in non-alcoholic steatohepatitis: a systematic review. BMC Gastroenterol. 2013;13:140. doi: 10.1186/1471-230X-13-140
- Кучерявый Ю.А., Черемушкин С.В. Оценка терапевтической эффективности референтного препарата урсодезоксихолевой кислоты и его аналогов в растворении билиарного сладжа: метаанализ. Consilium Medicum. 2022;24(12):860-4 [Kucheryavyy YA, Cheremushkin SV. Therapeutic efficacy evaluation of the reference drug ursodeoxycholic acid and its analogues in the biliary sludge dissolution: a meta-analysis. Consilium Medicum. 2022;24(12):860-4 (in Russian)].
Supplementary files
